Antipyrine clearance in chronic and neoplastic liver diseases: A study of 518 patients

Journal of Gastroenterology and Hepatology (Australia)

Volumn 13, Issue 5, 1998, Pages 460-466

  Grieco, Antonio ^a   Castellano, Rosario ^a   Matera, Anna ^a   Marcoccia, Stefania ^a   Di Rocco, Paola ^a   Ragazzoni, Enzo ^a   Vecchio, Fabio Maria ^a   Gasbarrini, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Antipyrine clearance; Chronic active hepatitis; Cirrhosis; Hepatocellular; Liver cancer; Liver metastases

Indexed keywords

PHENAZONE; PROTHROMBIN; SERUM ALBUMIN;

ADULT; AGED; ARTICLE; CHRONIC ACTIVE HEPATITIS; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER FUNCTION; LIVER METASTASIS; LIVER TUMOR; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTHROMBIN TIME;

EID: 0031835527     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1998.tb00668.x     Document Type: Article

References (37)

1. Andreasen PB, Ranek L, Statland E, Tygstrup N. Clearance of antipyrine-dependence of quantitative liver function. Eur. J. Clin. Invest. 1974; 4: 129-34.
2. Poulsen HE and Loft S. Quantification of Liver Function: Antipyrine Metabolism, an Update. In: Okolicsanyi L, Csomos G, Crepaldi G, eds. Assessment and Management of Hepatobiliary Disease. Berlin Heidelberg: Springer-Verlag, 1987; 189-95.
3. Strazzabosco M, Muraca M, Venuti M et al. Antipyrine Clearance: evaluation of simplified methods in chronic liver diseases. In: Okolicsanyi L, Csomos G, Crepaldi G, eds. Assessment and Management of Hepatobiliary Disease. Berlin Heidelberg: Springer-Verlag, 1987; 197-204.
4. Poulsen H, Loft S. Antipyrine as a model drug to study hepatic drug-metabolizing capacity. J. Hepatol. 1988; 6: 374-82.
5. Jalan R, Hayes PC. Review article: Quantitative tests of liver function. Aliment. Pharmacol. Ther. 1995; 9: 263-70.
6. Bremmelgaard A, Ranek L, Bahnsen M, Andreasen PB, Christensen E. Cholic acid conjugation test and quantitative liver function in acute liver failure. Scand. J. Gastroenterol. 1983; 18: 797-802.
7. Teunissen MW, Spoelstra P, Koch CW et al. Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis. Br. J. Clin. Pharmacol. 1984; 18: 707-15.
8. Wensing G, Ohnhaus E, Hoensch HP. Antipyrine elimination and hepatic microsomal enzyme activity in patients with liver disease. Clin. Pharmacol. Ther. 1990; 47: 698 705.
9. Wensing G, Hoffmann K, Heidemann HT. Antipyrine elimination in patients with alcoholic and non-alcoholic cirrhosis. Z. Gastroenterol. 1993; 31: 15-19.
10. Moltke LV, Abernethy DR, Kaplan MM, Greenblatt DJ. Antipyrine kinetics in patients with primary biliary cirrhosis J. Clin. Pharmacol. 1993; 33: 75-8.
11. Bauer LA, O'Sullivan T, Reiss WG et al. Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis. Br. J. Clin. Pharmacol. 1994; 37: 375-81.
12. Ali HA, El-Yazigi A, Sieck JO ct at. Antipyrine clearance and metabolite excretion in patients with chronic hepatitis C. J. Hepatol. 1995; 22: 17-21.
13. Sotaniemi EA, Pelkonene RO, Mokka RE, Huttunen R, Viljakainen E. Impairment of drug metabolism in patients with liver cancer. Eur. J. Clin. Invest. 1977; 7: 269-74.
14. Kairaluoma MI, Mokka RE, Sotaniemi EA, Huttunen R, Lattinen S, Larmi KI. Effect of surgery on liver function in patients with liver cancer. Scand. J. Gastroenterol. 1982; 17: 753-9.
15. Preiss R, Matthias M, Sohr R, Brockmann B, Huiler H. Pharmacokinetics of adriamycin, adriamycinol and antipyrine in patients with moderate tumor involvement of the liver. J. Cancer Res. Clin. Oncol. 1987; 113: 593-8.
16. Grieco A, Barone C, Coletta P et al. Antipyrine metabolism in patients with liver metastases from colorectal cancer. Cancer 1992; 70: 1477-82.
17. Grieco A, Castellano R, Matera A, Ragazzoni E, Fontana T, Barone C. Antipyrine metabolism during chemotherapy with 5-fluorouracil plus folinic acid in patients with liver metastases from primary colorectal cancer. Am. J. Ther. 1994; 1: 255-9.
18. Robertz-Vaupel GM, Lindecken KD, Edeki T, Funke C, Belwon S, Dengler HJ. Disposition of antipyrine in patients with extensive metastatic liver disease. Eur. J. Clin. Pharmacol. 1992; 42: 465-9.
19. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J. Natl Cancer Inst. 1980; 65: 25-32.
20. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
21. Pugh RNH, Murray-Lyon IM, Dawson JI, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 1973; 60: 646-9.
22. Okuda K, Obata H, Nakajima Y, Ohtsuki T, Okazaki N, Ohnishi K. Prognosis of primary hepatocellular carcinoma. Hepatology 1984; 4: S3-6.
23. Ziebell J, Shaw-Stiffel T. Update on the use of metabolic probes to quantify liver function: caffeine versus lidocaine. Dig. Dis. 1995; 13: 239-50.
24. Vesell ES. The antipyrine test in clinical pharmacology: Conceptions and misconceptions. Clin. Pharmacol. Ther. 1979; 26: 275-86.
25. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M. Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxy-methylantipyrine, and norantipyrine formation. Clin. Pharmacol. Ther. 1996; 59: 613-23.
26. Sharer JE, Wrighton SA. Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab. Dispos. 1996; 24: 487-94.
27. Buters JTM, Zysset T, Reichen J. Metabolism of antipyrine in vivo in two rat models of liver cirrhosis. Biochem. Pharmacol. 1993; 46: 983-91.
28. Williams SJ, Farrell GC. Serial Antipyrine Clearance studies detect altered hepatic metabolic function during spontaneous and interferon-induced changes in chronic hepatitis B disease activity. Hepatology 1989; 10: 192-7.
29. Coverdale S, Byth K, Field J, Liddle C, Lin R, Farrell GC. Antipyrine clearance and response to interferon treatment in patients with chronic active hepatitis C. Hepatology 1995; 22: 1065-71.
30. Simmonds P, Mellor J, Craxi A et al. Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients. J. Hepatol. 1996; 24: 517-24.
31. Astrom A, DePierre JW, Eriksson L. Characterization of drug-metabolizing systems in hyperplastic nodules from the livers of rats receiving 2-acetylaminofluorene in their diet. Carcinogenesis 1983; 4: 577-81.
32. Roomi MW, Ho RK, Sarma DSR, Farber E. A common biochemical pattern in preneoplastic hepatocyte nodules generated in four different models in the rat. Cancer Res. 1985; 45: 564-71.
33. El-Mouelhi M, Didolkar MS, Elias EG, Guengerich FP, Kaufman FC. Hepatic drug-metabolizing enzymes in primary and secondary tumors of human liver. Cancer Res. 1987; 47: 460-6.
34. Feuer G. Hepatic metabolism and carcinogenesis. Its role in hepatoma and adenocarcinoma. Ann. NY Acad. Sci. 1988; 534: 541-51.
35. Habib SL, Srikanth NS, Scappaticci FA et al. Altered expression of Cytochrome P450 mRNA during chemical-induced hepatocarcinogenesis and following partial hepatectomy. Toxicol. Appl. Pharmacol. 1994; 124: 139-48.
36. Colombo M, De Franchis R, Del Ninno E et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N. Engl. J. Med, 1991; 325: 675-80.
37. Farrell GC, Coverdale SA. Antipyrine clearance and response to interferon therapy in chronic hepatitis. Hepatology 1997; 25: 501-2.